Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial
Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Stefania Gori(Ospedale Sacro Cuore Don Calabria), M. Cinefra(Ospedale A. Perrino), Ilaria Pastina(Ospedale Misericordia - Grosseto), Giovanna Magni(Istituto Oncologico Veneto), Gian Luca De Salvo(Istituto Oncologico Veneto), Alberto Zambelli, Gabriella Moretti(Istituti di Ricovero e Cura a Carattere Scientifico), Giancarlo Bisagni, Vito Amoroso(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Roberto Vicini, Claudia Andreetta(Ospedale Santa Maria della Misericordia di Udine), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Carmelo Bengala(Ospedale Misericordia - Grosseto), Gabriella Mariani(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Vittoria Dieci(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Antonella Ferro(Ospedale Santa Chiara), Teresa Beninato(Fondazione IRCCS Istituto Nazionale dei Tumori), Laura Orlando, Elisa Genovesi(University of Padua), Costanza De Rossi(Ospedale dell' Angelo), Saverio Cinieri(Ospedale A. Perrino)
Cited by 13
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879